Latest news

• AstraZeneca wins NICE backing for asthma injection

  The recommendation from England's cost effectiveness watchdog gives AZ's injection a toe-hold in the market, where GSK's Nucala and Teva's Cinqaero are already NICE-approved. ... choice.”. Boysen even pointed out that AZ's drug could have some

• FDA rejects GSK’s Nucala for COPD

  Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).

• Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

  Teva’s Cinqaero is also on the NICE-approved list of treatments for this severe and potentially life-threatening form of asthma, having gained recommendation last year.

• AZ’s Fasenra hit by COPD trial failure

  A third IL-5 inhibitor – Teva’s Cinqair/Cinqaero (reslizumab) – has been available since 2016 but in an intravenous formulation only, and the company’s attempts to develop a subcutaneous version

• AZ gets EMA green light for severe asthma drug Fasenra

  The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero. ... Fasenra (benralizumab) is the third IL-5-targetting drug approved for market after GlaxoSmithKline’s Nucala (mepolizumab) and Teva’s Cinqaero (reslizumab)